Literature DB >> 15693090

The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis.

Erdal Gilgil1, Cahit Kaçar, Tiraje Tuncer, Bülent Bütün.   

Abstract

OBJECTIVE: To determine bone mineral density (BMD) using the posteroanterior L2-L4 (PA) and lateral L3 (LAT-L3) projections of dual energy x-ray absorptiometry (DEXA) in patients with ankylosing spondylitis (AS), and to evaluate the relationship between BMD and the presence of syndesmophytes.
METHODS: Twenty men with AS were studied. BMD was measured by femoral neck DEXA, PA DEXA, and LAT-L3 DEXA scans. Radiographs of lumbar spine were evaluated to obtain a lumbar spine score (LSS) for the presence of syndesmophytes. Twenty-three age matched healthy men served as controls.
RESULTS: While there was no significant difference in BMD from PA DEXA results between AS patients and controls, BMD from the LAT-L3 DEXA was significantly reduced in AS patients (p = 0.009). LSS correlated significantly with BMD from PA DEXA (r = 0.55, p = 0.013), but not with BMD of LAT-L3 DEXA.
CONCLUSION: LAT-L3 DEXA was superior to PA DEXA in detecting a decrease of BMD in patients with AS. The presence of syndesmophytes had no distorting effect on BMD measured by LAT-L3 DEXA.

Entities:  

Mesh:

Year:  2005        PMID: 15693090

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

1.  Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis.

Authors:  Ki-Jo Kim; Ji-Young Kim; Su-Jung Park; Hosung Yoon; Chong-Hyeon Yoon; Wan-Uk Kim; Chul-Soo Cho
Journal:  Clin Rheumatol       Date:  2012-05-30       Impact factor: 2.980

2.  Results of in situ fixation of Andersson lesion by posterior approach in 35 cases.

Authors:  B R Dave; M Kulkarni; V Patidar; D Devanand; S Mayi; C Reddy; M Singh; R R Rai; A Krishnan
Journal:  Musculoskelet Surg       Date:  2021-05-26

3.  Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis.

Authors:  Mehmet Ali Ulu; Remzi Çevik; Banu Dilek
Journal:  Rheumatol Int       Date:  2012-12-29       Impact factor: 2.631

4.  Bone mass in axial spondyloarthritis: A literature review.

Authors:  Erkan Kilic; Salih Ozgocmen
Journal:  World J Orthop       Date:  2015-03-18

5.  Maximum number of bone cross-linked vertebrae: an index for BMD in diffuse idiopathic skeletal hyperostosis.

Authors:  Mitsuru Furukawa; Kunimasa Okuyama; Ken Ninomiya; Yoshiyuki Yato; Takeshi Miyamoto; Masaya Nakamura; Morio Matsumoto
Journal:  J Bone Miner Metab       Date:  2021-11-29       Impact factor: 2.626

6.  Study of bone mineral density in patients with ankylosing spondylitis.

Authors:  Hatinder Jeet Singh; Kaur Nimarpreet; Sibadatta Das; Ashok Kumar; Shesh Prakash
Journal:  J Clin Diagn Res       Date:  2013-12-15

Review 7.  [Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors].

Authors:  H Franck; J Braun; F Buttgereit; W Demary; G Hein; J Kekow; G Schett; P M Kern
Journal:  Z Rheumatol       Date:  2009-12       Impact factor: 1.372

8.  The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis.

Authors:  Bedriye Mermerci Başkan; Yasemin Pekin Doğan; Filiz Sivas; Hatice Bodur; Kürşat Ozoran
Journal:  Rheumatol Int       Date:  2009-08-14       Impact factor: 2.631

9.  Alendronate Effect on the Prevention of Bone loss in Early Stages of Ankylosing Spondylitis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.

Authors:  Alireza Khabbazi; Hamid Noshad; Sevil Gafarzadeh; Mehrzad Hajialiloo; Susan Kolahi
Journal:  Iran Red Crescent Med J       Date:  2014-06-05       Impact factor: 0.611

10.  Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment.

Authors:  Eva Klingberg; Mattias Lorentzon; Dan Mellström; Mats Geijer; Jan Göthlin; Elisabet Hilme; Martin Hedberg; Hans Carlsten; Helena Forsblad-d'Elia
Journal:  Arthritis Res Ther       Date:  2012-05-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.